celecoxib has been researched along with Cancer of Nasopharynx in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the synergistic cytotoxicity of cis-dichlorodiamine platinum (DDP) and celecoxib on nasopharyngeal carcinoma TW03 cell which is resistant to DDP (TW03/DDP)." | 7.81 | [Combined application of cisplatin and celecoxib inhibits the proliferation and promotes apoptosis of nasopharyngeal carcinoma cells resistant to cisplatin]. ( Chen, J; Li, Q; Liu, S; Peng, J, 2015) |
| "The cell colony formation assay after the combination of celecoxib and radiation treatment was done on C666-1, CNE-1 and CNE-2 nasopharyngeal carcinoma cells, which expressed different COX-2 levels." | 7.80 | Celecoxib enhances radiosensitivity via induction of G₂-M phase arrest and apoptosis in nasopharyngeal carcinoma. ( Chen, WB; Huang, B; Liang, CH; Qiu, QH; Zhang, SX, 2014) |
| "To investigate the mechanisms underlying the anticancer effect of celecoxib on nasopharyngeal carcinoma (NPC)." | 7.78 | Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. ( Hu, GQ; Hu, GY; Liu, DB; Long, GX; Mei, Q; Qiu, H, 2012) |
| "Celecoxib is a selective inhibitor of COX-2, whose connection with the development and progression of human tumors has been extensively studied." | 5.40 | Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity. ( Gan, L; Hu, GQ; Hu, GY; Jiang, JZ; Li, WW; Liu, DB; Long, GX; Mei, Q; Sun, W; Wang, JF, 2014) |
| "To investigate the synergistic cytotoxicity of cis-dichlorodiamine platinum (DDP) and celecoxib on nasopharyngeal carcinoma TW03 cell which is resistant to DDP (TW03/DDP)." | 3.81 | [Combined application of cisplatin and celecoxib inhibits the proliferation and promotes apoptosis of nasopharyngeal carcinoma cells resistant to cisplatin]. ( Chen, J; Li, Q; Liu, S; Peng, J, 2015) |
| "The cell colony formation assay after the combination of celecoxib and radiation treatment was done on C666-1, CNE-1 and CNE-2 nasopharyngeal carcinoma cells, which expressed different COX-2 levels." | 3.80 | Celecoxib enhances radiosensitivity via induction of G₂-M phase arrest and apoptosis in nasopharyngeal carcinoma. ( Chen, WB; Huang, B; Liang, CH; Qiu, QH; Zhang, SX, 2014) |
| "To investigate the mechanisms underlying the anticancer effect of celecoxib on nasopharyngeal carcinoma (NPC)." | 3.78 | Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. ( Hu, GQ; Hu, GY; Liu, DB; Long, GX; Mei, Q; Qiu, H, 2012) |
| "Celecoxib combined with radiotherapy could induce apoptosis and enhance the radiosensitivity of human nasopharyngeal carcinoma CNE-2Z cell lines." | 3.77 | [Effects of celecoxib combined with radiotherapy on apoptosis of CNE-2Z cell lines]. ( Gui, P; Peng, P; Wei, LZ; Xiang, YZ; Xiong, ZJ; Yu, L, 2011) |
| "Celecoxib was administered at escalating doses of 400, 600, and 800mg/day, starting 3days before the first fraction of radiotherapy and continuing throughout the course of radiotherapy." | 2.76 | Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma. ( Bai, SM; Bi, ZF; Liu, YM; Luo, M; Wu, SK; Xue, WP, 2011) |
| "Celecoxib is a selective cyclooxygenase-2 inhibitor with antitumor and antiangiogenic activity." | 2.72 | Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. ( Aggarwal, A; Goh, BC; Hsieh, W; Hsu, S; Lai, YF; Loh, KS; Low, JS; Mow, B; Putti, T; Soo, RA; Soon, WL; Tan, KB; Tan, L; Tan, P; Tao, Q; Wu, J, 2006) |
| "Celecoxib is a selective inhibitor of COX-2, whose connection with the development and progression of human tumors has been extensively studied." | 1.40 | Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity. ( Gan, L; Hu, GQ; Hu, GY; Jiang, JZ; Li, WW; Liu, DB; Long, GX; Mei, Q; Sun, W; Wang, JF, 2014) |
| "Celecoxib can inhibit the growth of human nasopharyngeal carcinoma cell line CNE-2 and induce the cell apoptosis, which may be related to blocking the cell cycle progress of CNE-2 cells." | 1.35 | [Effects of celecoxib on the proliferation and apoptosis of human nasopharyngeal carcinoma cell line CNE-2]. ( Du, J; Fu, X; Huang, Q; Li, D; Xu, X; Yi, F, 2009) |
| " However, the tumors administered with a initial dose of CX at 24-h post-PDT had no tumor control." | 1.33 | Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma. ( Olivo, M; Soo, KC; Yee, KK, 2005) |
| "Celecoxib is a cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug (NSAID) which has been shown to be capable of inhibiting the growth of various cancer cell lines." | 1.33 | Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression. ( Chan, AT; Chan, CM; Ma, BB; Wong, SC, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, T | 1 |
| Fu, X | 2 |
| Qu, J | 1 |
| Zhang, M | 1 |
| Chen, H | 1 |
| Wang, Y | 1 |
| Wang, B | 1 |
| Li, J | 1 |
| Liu, J | 1 |
| Liu, P | 1 |
| Li, WW | 1 |
| Long, GX | 2 |
| Liu, DB | 2 |
| Mei, Q | 2 |
| Wang, JF | 1 |
| Hu, GY | 2 |
| Jiang, JZ | 1 |
| Sun, W | 1 |
| Gan, L | 1 |
| Hu, GQ | 2 |
| Zhang, SX | 1 |
| Qiu, QH | 1 |
| Chen, WB | 1 |
| Liang, CH | 1 |
| Huang, B | 1 |
| Chen, J | 1 |
| Liu, S | 1 |
| Li, Q | 1 |
| Peng, J | 1 |
| Xu, X | 1 |
| Yi, F | 1 |
| Li, D | 1 |
| Huang, Q | 1 |
| Du, J | 1 |
| Luo, WR | 1 |
| Li, LX | 1 |
| Li, SY | 1 |
| Jiang, HG | 1 |
| Chen, XY | 1 |
| Xue, WP | 1 |
| Bai, SM | 1 |
| Luo, M | 1 |
| Bi, ZF | 1 |
| Liu, YM | 1 |
| Wu, SK | 1 |
| Xiang, YZ | 1 |
| Wei, LZ | 1 |
| Yu, L | 1 |
| Gui, P | 1 |
| Peng, P | 1 |
| Xiong, ZJ | 1 |
| Qiu, H | 1 |
| Chen, PY | 1 |
| Long, QC | 1 |
| Yee, KK | 2 |
| Soo, KC | 2 |
| Olivo, M | 2 |
| Chan, CM | 1 |
| Ma, BB | 2 |
| Wong, SC | 1 |
| Chan, AT | 2 |
| Soo, RA | 1 |
| Wu, J | 1 |
| Aggarwal, A | 1 |
| Tao, Q | 1 |
| Hsieh, W | 1 |
| Putti, T | 1 |
| Tan, KB | 1 |
| Low, JS | 1 |
| Soon, WL | 1 |
| Lai, YF | 1 |
| Mow, B | 1 |
| Hsu, S | 1 |
| Loh, KS | 1 |
| Tan, L | 1 |
| Tan, P | 1 |
| Goh, BC | 1 |
| Jiang, DH | 1 |
| Guo, DY | 1 |
| Li, HZ | 1 |
| Deng, W | 1 |
| Bhuvaneswari, R | 1 |
| Gan, YY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Celecoxib on Concurrent Chemoradiation With Weekly Nedaplatin in Nasopharyngeal Carcinoma[NCT02537925] | Phase 3 | 120 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for celecoxib and Cancer of Nasopharynx
| Article | Year |
|---|---|
Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhibi | 2011 |
Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression.
Topics: Adult; Aged; Antineoplastic Agents; Blood Vessels; Celecoxib; Cyclooxygenase 2; Female; Gene Express | 2006 |
14 other studies available for celecoxib and Cancer of Nasopharynx
| Article | Year |
|---|---|
2,5-dimethyl celecoxib induces apoptosis and autophagy via activation of ROS/JNK axis in nasopharyngeal carcinoma cells.
Topics: Animals; Apoptosis; Autophagy; Celecoxib; Cell Line, Tumor; Cell Proliferation; Humans; JNK Mitogen- | 2021 |
Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity.
Topics: Carcinoma; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coloring Agents; Cyclooxy | 2014 |
Celecoxib enhances radiosensitivity via induction of G₂-M phase arrest and apoptosis in nasopharyngeal carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Celecoxib; Cell Cycle Checkpoints; Cell Division; Cell | 2014 |
[Combined application of cisplatin and celecoxib inhibits the proliferation and promotes apoptosis of nasopharyngeal carcinoma cells resistant to cisplatin].
Topics: Antineoplastic Agents; Carcinoma; Celecoxib; Cell Proliferation; Cisplatin; Drug Resistance, Neoplas | 2015 |
[Effects of celecoxib on the proliferation and apoptosis of human nasopharyngeal carcinoma cell line CNE-2].
Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Humans; Nas | 2009 |
[Influence of celecoxib on invasiveness of human high-metastatic nasopharyngeal carcinoma cell line CNE-2Z].
Topics: Apoptosis; Cadherins; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Gen | 2010 |
[Effects of celecoxib combined with radiotherapy on apoptosis of CNE-2Z cell lines].
Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma; Caspase 3; Celecoxib; Cell Line, Tumor; Humans; Na | 2011 |
Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma; Celecoxib; Cell Cycle Checkpoints; C | 2012 |
Effects of cyclooxygenase 2 inhibitors on biological traits of nasopharyngeal carcinoma cells.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Celeco | 2004 |
Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Anthracenes; Celecoxib; Cyclooxygenase 2; Drug Therapy, Combinatio | 2005 |
Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression.
Topics: Blotting, Western; Celecoxib; Cell Division; Cell Line, Tumor; Cyclin D1; Cyclooxygenase 2; Cyclooxy | 2005 |
Transcriptional profiling of tumor biopsies in oncology trials--a 'window' of opportunity for evaluating new drugs in nasopharyngeal cancer?
Topics: Antineoplastic Agents; Biopsy; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug | 2006 |
[Inhibited proliferation and expression of human nasopharyngeal carcinoma line induced by celecoxib in vitro].
Topics: Celecoxib; Cell Line, Tumor; Cell Proliferation; Humans; Nasopharyngeal Neoplasms; Pyrazoles; Sulfon | 2006 |
Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Anthracenes; Celecoxib; Gene Expression Regulation, Neoplastic; Hu | 2007 |